Company intelligence / Profile preview
Island Pharmaceuticals
Camberwell, Victoria, Australia
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
ISLA-101 has a well-established safety profile from 48 prior Phase I and II trials for other indications. Repurposed as an antiviral targeting dengue and related viruses, it has shown promising preclinical efficacy in animal models of dengue and Zika. A Phase 2a/b challenge clinical trial with both prophylactic and therapeutic arms has commenced
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Monash UniversityNational Cancer Institute INDU.S. Army Cooperative Research & Development Agreement
Beyond the preview
Go deeper on Island Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Island Pharmaceuticals.